Protagonist Therapeutics (PTGX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$143.73
+2.7% on the day
+114.4% over 12 months
52-week range $67.04 – $158.62
Share price and insider trades
PTGX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$96.2M
Insiders buying0
Insiders selling7
Protagonist Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $96.2M of PTGX stock on the open market.
Get emailed when insiders cluster-buy stocks like PTGX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
PTGX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $41.4M | 7 |
| Q2 2026 | — | 0 | $24.0M | 10 |
| Q1 2026 | — | 0 | $29.5M | 19 |
| Q4 2025 | — | 0 | $1.2M | 3 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.6×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Protagonist Therapeutics, Inc insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $96.2M. 13 of 39 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Asif AliCFO | Sell Plan | 46,03459,003 held (−44%) | $141.78 | $6.5M | +1.4% | — |
| Oct 2SEC | Asif AliCFO | Sell Plan | 12,595105,037 held (−11%) | $141.77 | $1.8M | +1.4% | — |
| Sep 10SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 63,548522,968 held (−11%) | $146.18 | $9.3M | -1.7% | — |
| Sep 10SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 54,174522,968 held (−9%) | $145.87 | $7.9M | -1.5% | — |
| Sep 10SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 7,278522,968 held (−1%) | $144.10 | $1.0M | -0.3% | — |
| Aug 12SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 65,761523,478 held (−11%) | $149.11 | $9.8M | -3.6% | — |
| Aug 12SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 34,239523,478 held (−6%) | $148.52 | $5.1M | -3.2% | — |
| Jun 25SEC | William D. WaddillDirector | Sell Plan | 9,0007,825 held (−53%) | $117.94 | $1.1M | +21.9% | — |
| Jun 11SEC | William D. WaddillDirector | Sell Plan | 9,0007,825 held (−53%) | $107.68 | $969K | +33.5% | — |
| Jun 1SEC | William D. WaddillDirector | Sell Plan | 9,0007,825 held (−53%) | $99.64 | $897K | +44.2% | — |
| May 14SEC | Dinesh V Ph D PatelCEO, President | Sell Plan | 75,000523,478 held (−13%) | $100.12 | $7.5M | +43.6% | — |
| May 12SEC | Dinesh V Ph D PatelCEO, President | Sell | 75,000523,478 held (−13%) | $100.12 | $7.5M | +43.6% | — |
| May 11SEC | Bryan GiraudoDirector | Sell | 36,00027,825 held (−56%) | $100.14 | $3.6M | +43.5% | — |
| May 11SEC | Bryan GiraudoDirector | Sell | 12,0006,000 held (−67%) | $100.07 | $1.2M | +43.6% | — |
| May 11SEC | Bryan GiraudoDirector | Sell | 6,000 | $100.00 | $600K | +43.7% | — |
| May 11SEC | Bryan GiraudoDirector | Sell | 5,13012,695 held (−29%) | $100.00 | $513K | +43.7% | — |
| Apr 21SEC | Asif AliCFO | Sell | 1,75059,003 held (−3%) | $105.47 | $185K | +36.3% | — |
| Mar 27SEC | Asif AliCFO | Sell | 24,76560,753 held (−29%) | $104.24 | $2.6M | +37.9% | — |
| Mar 27SEC | Harold E SelickDirector | Sell | 24,00060,845 held (−28%) | $105.00 | $2.5M | +36.9% | — |
| Mar 27SEC | Arturo Md MolinaChief Medical Officer | Sell | 15,00084,115 held (−15%) | $104.79 | $1.6M | +37.2% | — |
| Mar 25SEC | Dinesh V Ph D PatelCEO, President | Sell | 54,641524,938 held (−9%) | $101.00 | $5.5M | +42.3% | — |
| Mar 25SEC | Dinesh V Ph D PatelCEO, President | Sell | 59524,938 held (−0%) | $101.00 | $6K | +42.3% | — |
| Feb 18SEC | Lewis T WilliamsDirector | Sell | 18,0007,825 held (−70%) | $82.42 | $1.5M | +74.4% | — |
| Feb 6SEC | William D. WaddillDirector | Sell | 20,0007,825 held (−72%) | $83.68 | $1.7M | +71.8% | — |
| Jan 27SEC | Asif AliCFO | Sell | 28,00078,523 held (−26%) | $83.13 | $2.3M | +72.9% | — |
| Jan 27SEC | Dinesh V Ph D PatelCEO, President | Sell | 19,315574,505 held (−3%) | $84.59 | $1.6M | +69.9% | — |
| Jan 27SEC | Asif AliCFO | Sell | 18,20360,320 held (−23%) | $83.14 | $1.5M | +72.9% | — |
| Jan 27SEC | Dinesh V Ph D PatelCEO, President | Sell | 14,205574,505 held (−2%) | $84.05 | $1.2M | +71.0% | — |
| Jan 27SEC | Arturo Md MolinaChief Medical Officer | Sell | 13,15184,115 held (−14%) | $82.42 | $1.1M | +74.4% | — |
| Jan 27SEC | Dinesh V Ph D PatelCEO, President | Sell | 10,685574,505 held (−2%) | $84.00 | $898K | +71.1% | — |
| Jan 27SEC | Arturo Md MolinaChief Medical Officer | Sell | 5,00084,115 held (−6%) | $82.28 | $411K | +74.7% | — |
| Jan 27SEC | Arturo Md MolinaChief Medical Officer | Sell | 5,00084,115 held (−6%) | $82.00 | $410K | +75.3% | — |
| Jan 27SEC | Dinesh V Ph D PatelCEO, President | Sell | 4,068574,505 held (−1%) | $83.19 | $338K | +72.8% | — |
| Jan 21SEC | Dinesh V Ph D PatelCEO, President | Sell | 34,438580,505 held (−6%) | $82.48 | $2.8M | +74.3% | — |
| Jan 21SEC | Arturo Md MolinaChief Medical Officer | Sell | 9,51497,266 held (−9%) | $82.48 | $785K | +74.3% | — |
| Jan 21SEC | Asif AliCFO | Sell | 8,58878,077 held (−10%) | $82.48 | $708K | +74.3% | — |
| Nov 19SEC | Arturo Md MolinaChief Medical Officer | Sell | 2,71281,180 held (−3%) | $84.77 | $230K | +69.6% | — |
| Oct 14SEC | William D. WaddillDirector | Sell Plan | 8,0005,130 held (−61%) | $87.81 | $702K | +63.7% | — |
| Oct 14SEC | William D. WaddillDirector | Sell Plan | 4,00013,130 held (−23%) | $69.25 | $277K | +107.6% | — |
Insiders at Protagonist Therapeutics, Inc
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Dinesh V Ph D PatelCEO, President | — | $60.6M | Sep 10, 2026 | — |
| Asif AliCFO | — | $15.6M | Oct 2, 2026 | — |
| Bryan GiraudoDirector | — | $5.9M | May 11, 2026 | — |
| William D. WaddillDirector | — | $5.6M | Jun 25, 2026 | — |
| Arturo Md MolinaChief Medical Officer | — | $4.5M | Mar 27, 2026 | — |
| Harold E SelickDirector | — | $2.5M | Mar 27, 2026 | — |
| Lewis T WilliamsDirector | — | $1.5M | Feb 18, 2026 | — |
PTGX stock: common questions
Are Protagonist Therapeutics, Inc insiders buying PTGX stock?
In the past 12 months, 0 insiders reported open-market purchases of PTGX worth $0.
Are Protagonist Therapeutics, Inc insiders selling PTGX stock?
7 insiders reported sales worth $96.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PTGX's 52-week range?
Over the past year PTGX has traded between $67.04 and $158.62. It last closed at $143.73 on Oct 9, 2026.